The approval of several different classes of drugs in recent years has resulted in a dramatic expansion of treatment options for multiple myeloma patients, improving both survival and quality of life. Immunomodulatory drugs and proteasome inhibitors are core components of treatment at the time of diagnosis. Recent clinical trials using combinations of these drugs have demonstrated unprecedented improvements in efficacy while maintaining tolerability. These have afforded us the opportunity to aim for increasing depths of response and achievement of minimal residual disease state. Dr Raje will review recent data in the context of newly diagnosed patients both in the transplant and non-transplant patient population. She will then focus on special situations and discuss her treatment preferences.